{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-diabetic-neuropathy","title":"VIP for Diabetic Neuropathy: Evidence-Graded Overview","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\n\n## Why VIP might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\n\n## What the evidence actually shows\n\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\n\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\n\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\n\n## What scientists say\n\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neuropathy (mechanistic). Reduced VIP in diabetic nerves is noted as an observation without proven causal repair benefit in humans.\n\n## What people say on Reddit\n\nSearches returned no posts describing VIP use for diabetic neuropathy. Related discussions focus on other peptides like ARA-290 for neuropathic symptoms (anecdotal, unrelated compound).\n\n## What people say on X\n\nNo relevant X posts on VIP for diabetic neuropathy were identified.\n\n## What we do not know\n\nNo human trials test whether VIP administration improves nerve function, symptoms, or repair in diabetic neuropathy. Long-term effects, optimal delivery, and whether observed reductions in endogenous VIP are a cause or consequence remain unknown. Animal nerve regeneration data do not directly translate to human diabetic neuropathy.\n\n## Safety and limits\n\nVIP has been studied in limited human contexts for other conditions with reports of tolerability in small settings, but specific safety data for neuropathy applications are absent. Any use carries unknown risks given the lack of targeted evidence.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP immunoreactivity is reduced in cutaneous nerves of diabetic patients with peripheral neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human observation of VIP changes in diabetic neuropathy tissue.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP levels change during nerve regeneration in a rat model.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides animal basis for VIP in repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials exist for VIP in diabetic neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of clinical efficacy data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.1007/BF01826199","title":"The effects of vasoactive intestinal polypeptide and substance P on the cutaneous nerves of diabetic patients with peripheral neuropathy","quote":"Vasoactive intestinal polypeptide (VIP) and substance P (SP) immunoreactivity are reduced in the cutaneous nerves of diabetic patients with peripheral neuropathy.","summary":"1995 study showing reduced VIP in diabetic neuropathy skin nerves.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:32:40.909Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"0dd3dd6f4704c4ddfd9bda7d22f846b44e300beaba3eaf2bf83709f8fb548c0a"},{"id":"s2","type":"pubmed","url":"https://journals.sagepub.com/doi/10.1016/0266-7681(91)90106-X","title":"Vasoactive Intestinal Peptide and Nerve Regeneration","quote":"The role of vasoactive intestinal peptide (V.I.P.) in nerve regeneration was investigated by assessing the changes in immunoreactive V.I.P. levels in rat sciatic nerves.","summary":"Rat study on VIP changes during nerve regeneration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:32:40.909Z","link_status":"http_403","quote_status":"unverified","prev":"0dd3dd6f4704c4ddfd9bda7d22f846b44e300beaba3eaf2bf83709f8fb548c0a","hash":"2959a7186518661b09d6368e0bd2e8c13b45bf735811b7f76862b83df7af30f9"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:32:42.814Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Diabetic Neuropathy: Evidence-Graded Overview","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\n\n## Why VIP might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\n\n## What the evidence actually shows\n\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\n\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\n\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\n\n## What scientists say\n\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neuropathy (mechanistic). Reduced VIP in diabetic nerves is noted as an observation without proven causal repair benefit in humans.\n\n## What people say on Reddit\n\nSearches returned no posts describing VIP use for diabetic neuropathy. Related discussions focus on other peptides like ARA-290 for neuropathic symptoms (anecdotal, unrelated compound).\n\n## What people say on X\n\nNo relevant X posts on VIP for diabetic neuropathy were identified.\n\n## What we do not know\n\nNo human trials test whether VIP administration improves nerve function, symptoms, or repair in diabetic neuropathy. Long-term effects, optimal delivery, and whether observed reductions in endogenous VIP are a cause or consequence remain unknown. Animal nerve regeneration data do not directly translate to human diabetic neuropathy.\n\n## Safety and limits\n\nVIP has been studied in limited human contexts for other conditions with reports of tolerability in small settings, but specific safety data for neuropathy applications are absent. Any use carries unknown risks given the lack of targeted evidence.","claims":[{"id":"c1","text":"VIP immunoreactivity is reduced in cutaneous nerves of diabetic patients with peripheral neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human observation of VIP changes in diabetic neuropathy tissue.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP levels change during nerve regeneration in a rat model.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides animal basis for VIP in repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials exist for VIP in diabetic neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of clinical efficacy data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.1007/BF01826199","title":"The effects of vasoactive intestinal polypeptide and substance P on the cutaneous nerves of diabetic patients with peripheral neuropathy","quote":"Vasoactive intestinal polypeptide (VIP) and substance P (SP) immunoreactivity are reduced in the cutaneous nerves of diabetic patients with peripheral neuropathy.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://journals.sagepub.com/doi/10.1016/0266-7681(91)90106-X","title":"Vasoactive Intestinal Peptide and Nerve Regeneration","quote":"The role of vasoactive intestinal peptide (V.I.P.) in nerve regeneration was investigated by assessing the changes in immunoreactive V.I.P. levels in rat sciatic nerves.","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":14408,"tokens_out":1828,"cost":0.02258,"prev_hash":"genesis","hash":"6ade25eface3cc46a224c698b50eb493564001ae673a1e5148f0fe685281ac28"}],"provenance":[{"ts":"2026-06-29T22:32:42.814Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Diabetic Neuropathy\nSlug: vip-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down if you have Diabetic neuropathy\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence ","response":"{\n  \"slug\": \"vip-diabetic-neuropathy\",\n  \"title\": \"VIP for Diabetic Neuropathy: Evidence-Graded Overview\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\\n\\n## Why VIP might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\\n\\n## How these fit together\\n\\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\\n\\n## What the evidence actually shows\\n\\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\\n\\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\\n\\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\\n\\n## What scientists say\\n\\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neu","tokens_in":14408,"tokens_out":1828,"cost":0,"prev":"genesis","hash":"0199b89305b21b0093fa3e1a5db741d82fd8101a6c9eaed4649c6343326ba3c0"},{"ts":"2026-07-17T02:43:23.220Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-diabetic-neuropathy","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0199b89305b21b0093fa3e1a5db741d82fd8101a6c9eaed4649c6343326ba3c0","hash":"4fb3194d3dbde6d720cac3b5248ef67c48b3162dc2a0f64f9e6b46dc76d1babf"}],"energy":{"passes":2,"tokens_in":14408,"tokens_out":1828,"tokens_total":16236,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"4fb3194d3dbde6d720cac3b5248ef67c48b3162dc2a0f64f9e6b46dc76d1babf"},"posted_at":"2026-06-29T21:33:49.559Z","created_at":"2026-06-29T21:33:49.559Z","updated_at":"2026-07-17T02:43:23.220Z","machine":{"shape":"article.machine/v1","slug":"vip-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-diabetic-neuropathy","json":"/api/articles/vip-diabetic-neuropathy","markdown":"/api/articles/vip-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/vip-diabetic-neuropathy/skill","topology":"/api/articles/vip-diabetic-neuropathy/topology","versions":"/api/articles/vip-diabetic-neuropathy/revisions","invocations":"/api/articles/vip-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"afd2826e63db8c9285c0d05fd764c5fc534e4dd364d3c8256d3c22c8090ca24c","object":{"object_type":"article-object","identity":{"id":"article:vip-diabetic-neuropathy","slug":"vip-diabetic-neuropathy","title":"VIP for Diabetic Neuropathy: Evidence-Graded Overview"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-diabetic-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-diabetic-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-diabetic-neuropathy\ndescription: Apply the VIP for Diabetic Neuropathy: Evidence-Graded Overview article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP for Diabetic Neuropathy: Evidence-Graded Overview\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-diabetic-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-diabetic-neuropathy.\n- Read claims and relationships at /api/articles/vip-diabetic-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Diabetic neuropathy Diabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, \n\n## Representations\n\n- Human: /a/vip-diabetic-neuropathy\n- JSON: /api/articles/vip-diabetic-neuropathy\n- Relationships: /api/articles/vip-diabetic-neuropathy/topology\n- History: /api/articles/vip-diabetic-neuropathy/revisions\n"},"json":{"route":"/api/articles/vip-diabetic-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-diabetic-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","diabetic","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-diabetic-neuropathy/invocations?status=success","failure_events":"/api/articles/vip-diabetic-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-diabetic-neuropathy","title":"VIP for Diabetic Neuropathy: Evidence-Graded Overview","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\n\n## Why VIP might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\n\n## What the evidence actually shows\n\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\n\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\n\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\n\n## What scientists say\n\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neuropathy (mechanistic). Reduced VIP in diabetic nerves is noted as an observation without proven causal repair benefit in humans.\n\n## What people say on Reddit\n\nSearches returned no posts describing VIP use for diabetic neuropathy. Related discussions focus on other peptides like ARA-290 for neuropathic symptoms (anecdotal, unrelated compound).\n\n## What people say on X\n\nNo relevant X posts on VIP for diabetic neuropathy were identified.\n\n## What we do not know\n\nNo human trials test whether VIP administration improves nerve function, symptoms, or repair in diabetic neuropathy. Long-term effects, optimal delivery, and whether observed reductions in endogenous VIP are a cause or consequence remain unknown. Animal nerve regeneration data do not directly translate to human diabetic neuropathy.\n\n## Safety and limits\n\nVIP has been studied in limited human contexts for other conditions with reports of tolerability in small settings, but specific safety data for neuropathy applications are absent. Any use carries unknown risks given the lack of targeted evidence.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP immunoreactivity is reduced in cutaneous nerves of diabetic patients with peripheral neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human observation of VIP changes in diabetic neuropathy tissue.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP levels change during nerve regeneration in a rat model.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides animal basis for VIP in repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials exist for VIP in diabetic neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of clinical efficacy data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.1007/BF01826199","title":"The effects of vasoactive intestinal polypeptide and substance P on the cutaneous nerves of diabetic patients with peripheral neuropathy","quote":"Vasoactive intestinal polypeptide (VIP) and substance P (SP) immunoreactivity are reduced in the cutaneous nerves of diabetic patients with peripheral neuropathy.","summary":"1995 study showing reduced VIP in diabetic neuropathy skin nerves.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:32:40.909Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"0dd3dd6f4704c4ddfd9bda7d22f846b44e300beaba3eaf2bf83709f8fb548c0a"},{"id":"s2","type":"pubmed","url":"https://journals.sagepub.com/doi/10.1016/0266-7681(91)90106-X","title":"Vasoactive Intestinal Peptide and Nerve Regeneration","quote":"The role of vasoactive intestinal peptide (V.I.P.) in nerve regeneration was investigated by assessing the changes in immunoreactive V.I.P. levels in rat sciatic nerves.","summary":"Rat study on VIP changes during nerve regeneration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:32:40.909Z","link_status":"http_403","quote_status":"unverified","prev":"0dd3dd6f4704c4ddfd9bda7d22f846b44e300beaba3eaf2bf83709f8fb548c0a","hash":"2959a7186518661b09d6368e0bd2e8c13b45bf735811b7f76862b83df7af30f9"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:32:42.814Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Diabetic Neuropathy: Evidence-Graded Overview","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\n\n## Why VIP might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\n\n## How these fit together\n\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\n\n## What the evidence actually shows\n\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\n\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\n\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\n\n## What scientists say\n\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neuropathy (mechanistic). Reduced VIP in diabetic nerves is noted as an observation without proven causal repair benefit in humans.\n\n## What people say on Reddit\n\nSearches returned no posts describing VIP use for diabetic neuropathy. Related discussions focus on other peptides like ARA-290 for neuropathic symptoms (anecdotal, unrelated compound).\n\n## What people say on X\n\nNo relevant X posts on VIP for diabetic neuropathy were identified.\n\n## What we do not know\n\nNo human trials test whether VIP administration improves nerve function, symptoms, or repair in diabetic neuropathy. Long-term effects, optimal delivery, and whether observed reductions in endogenous VIP are a cause or consequence remain unknown. Animal nerve regeneration data do not directly translate to human diabetic neuropathy.\n\n## Safety and limits\n\nVIP has been studied in limited human contexts for other conditions with reports of tolerability in small settings, but specific safety data for neuropathy applications are absent. Any use carries unknown risks given the lack of targeted evidence.","claims":[{"id":"c1","text":"VIP immunoreactivity is reduced in cutaneous nerves of diabetic patients with peripheral neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human observation of VIP changes in diabetic neuropathy tissue.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP levels change during nerve regeneration in a rat model.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides animal basis for VIP in repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials exist for VIP in diabetic neuropathy treatment.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of clinical efficacy data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:32:42.036Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://link.springer.com/article/10.1007/BF01826199","title":"The effects of vasoactive intestinal polypeptide and substance P on the cutaneous nerves of diabetic patients with peripheral neuropathy","quote":"Vasoactive intestinal polypeptide (VIP) and substance P (SP) immunoreactivity are reduced in the cutaneous nerves of diabetic patients with peripheral neuropathy.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://journals.sagepub.com/doi/10.1016/0266-7681(91)90106-X","title":"Vasoactive Intestinal Peptide and Nerve Regeneration","quote":"The role of vasoactive intestinal peptide (V.I.P.) in nerve regeneration was investigated by assessing the changes in immunoreactive V.I.P. levels in rat sciatic nerves.","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":14408,"tokens_out":1828,"cost":0.02258,"prev_hash":"genesis","hash":"6ade25eface3cc46a224c698b50eb493564001ae673a1e5148f0fe685281ac28"}],"provenance":[{"ts":"2026-06-29T22:32:42.814Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Diabetic Neuropathy\nSlug: vip-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down if you have Diabetic neuropathy\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence ","response":"{\n  \"slug\": \"vip-diabetic-neuropathy\",\n  \"title\": \"VIP for Diabetic Neuropathy: Evidence-Graded Overview\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive nerve fiber damage linked to chronic high blood sugar. Layers include axonal degeneration, reduced nerve blood flow, immune activation in nerves, and autonomic imbalance. These processes shift the balance toward breakdown outrunning repair in peripheral nerves.\\n\\n## Why VIP might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nVIP has been studied for effects on nerve tissue repair pathways and autonomic signaling. If immune modulation or autonomic support aligns with the layers affected in your case, that forms the basis for discussion.\\n\\n## How these fit together\\n\\nSingle-compound focus. VIP targets the immune / autonomic layer listed in the condition profile.\\n\\n## What the evidence actually shows\\n\\nHuman data: One 1995 study measured VIP immunoreactivity in skin biopsies from diabetic patients with peripheral neuropathy and found reduced VIP levels in cutaneous nerves compared to controls (human observational). No randomized human trials of VIP administration for diabetic neuropathy were identified.\\n\\nPreclinical data: A rat study examined VIP levels during nerve regeneration and reported changes in immunoreactive VIP (preclinical). VIP showed anti-inflammatory effects in animal models of arthritis (preclinical).\\n\\nAnecdotal data: No direct Reddit or X reports specifically linking VIP use to diabetic neuropathy outcomes were found in searched results.\\n\\n## What scientists say\\n\\nReviews note VIP's roles in glucose-dependent insulin secretion and potential immune effects, but do not establish clinical use for neu","tokens_in":14408,"tokens_out":1828,"cost":0,"prev":"genesis","hash":"0199b89305b21b0093fa3e1a5db741d82fd8101a6c9eaed4649c6343326ba3c0"},{"ts":"2026-07-17T02:43:23.220Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-diabetic-neuropathy","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0199b89305b21b0093fa3e1a5db741d82fd8101a6c9eaed4649c6343326ba3c0","hash":"4fb3194d3dbde6d720cac3b5248ef67c48b3162dc2a0f64f9e6b46dc76d1babf"}],"energy":{"passes":2,"tokens_in":14408,"tokens_out":1828,"tokens_total":16236,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"4fb3194d3dbde6d720cac3b5248ef67c48b3162dc2a0f64f9e6b46dc76d1babf"},"posted_at":"2026-06-29T21:33:49.559Z","created_at":"2026-06-29T21:33:49.559Z","updated_at":"2026-07-17T02:43:23.220Z","machine":{"shape":"article.machine/v1","slug":"vip-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-diabetic-neuropathy","json":"/api/articles/vip-diabetic-neuropathy","markdown":"/api/articles/vip-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/vip-diabetic-neuropathy/skill","topology":"/api/articles/vip-diabetic-neuropathy/topology","versions":"/api/articles/vip-diabetic-neuropathy/revisions","invocations":"/api/articles/vip-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"afd2826e63db8c9285c0d05fd764c5fc534e4dd364d3c8256d3c22c8090ca24c"}}}